Investigative product portfolio
Our Global Internal Discovery Pipeline Covers the Vast Majority of the World’s Cancers1
One of the world’s largest oncology research teams (950+) with 60+ preclinical programs and ~50 assets in clinical and commercialization stages
Solid Tumors
Hematology
Inflammation and Immunology
Abbreviations: 1L, first-line; 2L, second-line; 3L, third-line; BC, breast cancer; cHL, classical
Hodgkin
lymphoma;
BRAF, B-rapidly accelerated fibrosarcoma; CLL, chronic lymphocytic leukemia; CSF-1R, colony stimulating
factor-1
receptor; ESCC, esophageal squamous cell carcinoma; FGFR, fibroblast growth factor receptor; FL, follicular
lymphoma;
GC, gastric cancer; GEA, gastroesophageal adenocarcinoma; GEJC, gastroesophageal junction carcinoma; HCC,
hepatocellular
carcinoma; LS-SCLC, limited-stage small cell lung cancer; MCL, mantle cell lymphoma; MEK, MAP/ERK kinase; MZL,
marginal
zone lymphoma; NSCLC, non–small cell lung cancer; PD-L1, programmed death ligand-1; R/R, relapsed/refractory;
SLL, small
lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; VEGFR, vascular endothelial
growth factor
receptor.
aEnrolling in the United States.
bThis combination is being studied in the third cohort of SEQUOIA (NCT03336333).
cFirst-in-human trial, healthy subjects.
References: 1. BeiGene Corporate Presentation; January 9, 2023. 2. Study of BGB-11417 in participants with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ClinicalTrials.gov identifier: NCT05479994. Accessed July 31, 2023. https://clinicaltrials.gov/ct2/show/NCT05479994